Medlive Technology Co., Ltd. provided earnings guidance for the year ended 31 December 2023. For the year, the Board expects the revenue for FY2023 to increase to not less than RMB 410 million from the revenue for the financial year ended 31 December 2022 of RMB314 million, and a significant increase in profit attributable to owners of the parent for FY2023 to not less than RMB235 million as compared to the profit attributable to owners of the parent of approximately RMB 117.3 million for the year ended 31 December 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.26 HKD | +1.35% | +10.87% | -2.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.59% | 757M | |
+24.29% | 27.88B | |
+10.84% | 18.78B | |
+8.39% | 13.65B | |
-3.58% | 11.88B | |
+7.89% | 10.86B | |
+7.47% | 4.45B | |
-12.44% | 3.74B | |
+35.03% | 3.4B | |
+16.26% | 3.31B |
- Stock Market
- Equities
- 2192 Stock
- News Medlive Technology Co., Ltd.
- Medlive Technology Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2023